読み込み中
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
前日終値
$17.88
+$0.47 · +2.70%
日中の時刻はETです。市場データは遅延する場合があります。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $17.88
52週レンジ
現在 $17.88
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
58
まちまち
リスク
46
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $17.88
52週レンジ
現在 $17.88
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1535.5万 USD | 1000.7万 USD | 2554.6万 USD | 138.1万 USD | 302.9万 USD |
| 売上原価 | 355.7万 USD | 3.15億 USD | 3.26億 USD | 2.43億 USD | 1.69億 USD |
| 粗利益 | 1179.8万 USD | −3.05億 USD | −3.01億 USD | −2.42億 USD | −1.66億 USD |
| 研究開発 | 2.61億 USD | 3.19億 USD | 3.3億 USD | 2.46億 USD | 2.96億 USD |
| 販売・一般管理 | 5671万 USD | 8024万 USD | 7858.1万 USD | 6932.8万 USD | 5974.8万 USD |
| 営業費用 | 3.15億 USD | 6703.4万 USD | 7215.9万 USD | 5765.1万 USD | 1.98億 USD |
| 受取利息 | 2703.5万 USD | 3474.6万 USD | 3104.5万 USD | 878.6万 USD | 83万 USD |
| 減価償却費と償却費 | 355.7万 USD | 546.4万 USD | 526.9万 USD | 413万 USD | 392.5万 USD |
| 営業利益 | −3.03億 USD | −3.72億 USD | −3.73億 USD | −2.99億 USD | −3.65億 USD |
| 純利益 | −2.76億 USD | −3.38億 USD | −3.42億 USD | −2.91億 USD | −3.64億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$26.25
上昇余地（46.81%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.25億0.01%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI8580.4万0.87%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM8355.01万0.11%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3620.53万0.04%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB2311.14万0.22%102.79億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO2304.82万0.17%139.72億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS2193.74万0.06%338.69億 USD0.31%$78.35+0.32%
T. Rowe Capital Appreciation Equity ETFTCAF1755.31万0.19%90.1億 USD0.31%$43.59+0.90%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFAST. Rowe Capital Appreciation Equity ETFTCAFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
